Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Pramipexole 2HCl Monohydrate

SKU: orb1222570

Description

Pramipexole Dihydrochloride is a D2/3 agonist. It acts by reducing mitochondrial ROS production and inhibiting the activation of apoptotic pathways.(In Vitro):Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.(In Vivo):Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number191217-81-9
MW302.26
Purity>98% (HPLC)
FormulaC10H17N3S·2HCl·H2O
SMILESO.Cl.CCCN[C@H]1CCc2c(C1)sc(N)n2.Cl
TargetD2S|D2L|D3|D4
SolubilityIn Vitro: H2O : 100 mg/mL (330.84 mM)

Bioactivity

In Vivo
Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals. Pramipexole dihydrochloride hydrate improves neurological recovery. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Animal model: Male Wistar rats weighing 250-300 g (16-18 weeks old). Dosage: 0.25 mg/kg, 1 mg/kg. Administration: Intraperitoneal injection. Result: Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.
In Vitro
Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50, 000 nM. Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Pramipexole Dihydrochloride Monohydrate | Pramipexole Dihydrochloride

Similar Products

  • Pramipexole dihydrochloride hydrate [orb1300317]

    99.55% (May vary between batches)

    191217-81-9

    302.26

    C10H17N3S·2HCl·H2O

    1 ml x 10 mM (in DMSO), 500 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Pramipexole 2HCl Monohydrate (orb1222570)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

500 mg
10 mg
$ 80.00
25 mg
$ 130.00
50 mg
$ 210.00
100 mg
$ 290.00
200 mg
$ 430.00